We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

91 hedge funds and large institutions have $406M invested in Calithera Biosciences, Inc in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 26

6% more capital invested

Capital invested by funds: $382M → $406M (+$24M)

3% less funds holding

Funds holding: 9491 (-3)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

30% less call options, than puts

Call options by funds: $1.42M | Put options by funds: $2.04M

Holders
91
Holders Change
-3
Holders Change %
-3.19%
% of All Funds
2.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
35
Reduced
26
Closed
17
Calls
$1.42M
Puts
$2.04M
Net Calls
-$618K
Net Calls Change
+$1.18M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$73.7M +$1.63M +5,181 +2%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$54.3M -$10.6M -33,750 -16%
Viking Global Investors
3
Viking Global Investors
Connecticut
$41.3M +$3.22M +10,211 +8%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$33.7M -$9.15M -29,019 -21%
BlackRock
5
BlackRock
New York
$33.1M +$642K +2,036 +2%
State Street
6
State Street
Massachusetts
$24.5M +$3.92M +12,423 +19%
Vanguard Group
7
Vanguard Group
Pennsylvania
$17.3M -$1.57M -4,979 -8%
Franklin Resources
8
Franklin Resources
California
$11.8M
AC
9
Ascend Capital
California
$10.4M +$3.86M +12,230 +59%
Lord, Abbett & Co
10
Lord, Abbett & Co
New Jersey
$9.93M +$2.09M +6,622 +27%
AQR Capital Management
11
AQR Capital Management
Connecticut
$7.82M +$7.27M +23,056 +1,311%
Millennium Management
12
Millennium Management
New York
$7.59M +$3.98M +12,628 +110%
Citadel Advisors
13
Citadel Advisors
Florida
$7.57M -$1.43M -4,526 -16%
American Century Companies
14
American Century Companies
Missouri
$6.69M +$4.9M +15,541 +273%
Northern Trust
15
Northern Trust
Illinois
$5.26M -$54.6K -173 -1%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$4.61M +$928K +2,943 +25%
ACM
17
Atika Capital Management
New York
$3.69M -$401K -1,270 -10%
CS
18
Candriam SCA
Luxembourg
$3.46M -$759K -2,405 -18%
TCIM
19
TIAA CREF Investment Management
New York
$2.98M +$86.7K +275 +3%
IBT
20
International Biotechnology Trust
United Kingdom
$2.95M -$883K -2,800 -23%
PAM
21
Panagora Asset Management
Massachusetts
$2.9M +$1.19M +3,787 +70%
AG
22
Artal Group
Luxembourg
$2.76M -$394K -1,250 -13%
Deutsche Bank
23
Deutsche Bank
Germany
$2.64M +$1.71M +5,435 +185%
Renaissance Technologies
24
Renaissance Technologies
New York
$2.51M +$2.52M +7,975 New
Invesco
25
Invesco
Georgia
$2.41M +$2.41M +7,640 New

CALA Hedge Fund Activity: Q3 2017 in Review

91 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q3 2017, worth a combined $406M — up 6.3% from $382M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CALA and 14 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 35 added.

The largest buyer was AQR Capital Management, adding an estimated $7.27M. The largest seller was Adage Capital Partners, cutting an estimated $10.6M.

  • 91 institutional investors held Calithera Biosciences, Inc (CALA) as of Q3 2017, down from 94 in Q2 2017.
  • Funds reported $406M of Calithera Biosciences, Inc stock for Q3 2017, up 6.3% quarter-over-quarter.
  • 14 funds opened new Calithera Biosciences, Inc positions in Q3 2017 and 17 closed out, a net change of -3 holders.
  • The largest Calithera Biosciences, Inc buyer in Q3 2017 was AQR Capital Management, an estimated $7.27M added.
  • The largest Calithera Biosciences, Inc seller in Q3 2017 was Adage Capital Partners, an estimated $10.6M sold.

Based on aggregated 13F filings for Q3 2017.